

pegaspargase (Oncaspar)

Medical Benefit Drug Policy

Place of Service

Office Administration

Outpatient Facility Administration

Infusion Center Administration

Home Infusion Administration

Drug Details

USP Category: Class: Antineoplastics

Mechanism of Action: Antineoplastic Agent

HCPCS: J3490, J3590, J9999

NDC(s):

- 72694-954-01: 3,750 international units [IU]/5 mL (750 IU/mL) single-dose vial
1. All requests for pegaspargase (Oncaspar) must receive authorization prior to drug administration for claim payment.
 2. Criteria for coverage is pending P&T Committee approval.
 3. In the interim, all requests for coverage will be reviewed for medical necessity.

References

1. Oncaspar (pegaspargase). [Prescribing information]. Boston, MA: Servier Pharmaceuticals LLC; 12/2022.